The risk of cerebral vein thrombosis, which caused many regulators to pause or discontinue using AstraZeneca’s and J&J vaccines, appears to be very similar for AstraZeneca’s vaccine (5 in a million) as for Pfizer’s and Moderna’s mRNA vaccines (4 in a million). pic.twitter.com/KZcMCIQVXd

— Sputnik V (@sputnikvaccine) April 16, 2021